Compare · PRPO vs TXG
PRPO vs TXG
Side-by-side comparison of Precipio Inc. (PRPO) and 10x Genomics Inc. (TXG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PRPO and TXG operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- TXG is the larger of the two at $7.65B, about 192.9x PRPO ($39.7M).
- TXG has been more active in the news (10 items in the past 4 weeks vs 7 for PRPO).
- TXG has more recent analyst coverage (25 ratings vs 0 for PRPO).
- Company
- Precipio Inc.
- 10x Genomics Inc.
- Price
- -
- -
- Market cap
- $39.7M
- $7.65B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 7
- 10
- Recent ratings
- 0
- 25
Precipio Inc.
Precipio, Inc., a cancer diagnostics and reagent technology company, provides diagnostic products and services in the United States oncology market. Its product consists of clinical diagnostic services. The company's clinical diagnostic services focus on the diagnosis of different hematopoietic or blood-related cancers to oncologists. Its cytogenetics media IV-Cell enables laboratories to arrive at more accurate results; HemeScreen panel enables hospitals and laboratories to run an important genetic mutation test; and ICE-COLD-PCR enables detection of abnormalities in blood samples. The company also operates a cancer diagnostic laboratory located in New Haven, Connecticut. It sells ICE-COLD-PCR technology kits to bio-pharma customers, clinical research, HemeScreen, and COVID-19 antibody tests. The company serves oncologists, hospitals, reference laboratories, physician-office labs, and pharma and biotech companies. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, such as the Yale School of Medicine, Harvard's Dana-Farber Cancer Institute, and the University of Pennsylvania. The company is based in New Haven, Connecticut.
10x Genomics Inc.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Latest PRPO
- SEC Form 10-Q filed by Precipio Inc.
- Precipio Announces Q3-2026 Financial Results
- Precipio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 8-K filed by Precipio Inc.
- Precipio Announces Q3-2026 Shareholder Update Call
- SEC Form 4 filed by Precipio Inc.
- SEC Form 4 filed by Precipio Inc.
- Precipio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Precipio Announces Q2-2026 Financial Results
- Precipio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Latest TXG
- Chief Executive Officer Saxonov Serge sold $1,949,900 worth of shares (31,000 units at $62.90), decreasing direct ownership by 3% to 1,019,249 units (SEC Form 4)
- Shanghai Precision Diagnostics and Fudan University Shanghai Cancer Center Launch Breast Cancer Biomarker Study Using 10x Genomics' Xenium Platform
- SEC Form 3 filed by new insider Satpathy Ansuman
- New insider Gilliam Joseph E claimed ownership of 31 shares (SEC Form 3)
- 10x Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- 10x Genomics Reports Third Quarter 2026 Financial Results
- 10x Genomics Inc. filed SEC Form 8-K: Leadership Update
- 10x Genomics Launches Sentira Single Cell, A New Agentic AI Experience for Chromium Analysis
- 10x Genomics to Participate in the 2026 Jefferies Global Healthcare Conference
- 10x Genomics downgraded by Stephens